Mutations driving CLL and their evolution in progression and relapse
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and therapy are central questions in cancer biology. Here we identify 44 recurrently mutated genes and 11 recurrent somatic copy number variations through whole-exome sequencing of 538 chronic lymphocytic le...
Main Author: | Lander, Eric Steven |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | en_US |
Published: |
Nature Publishing Group
2017
|
Online Access: | http://hdl.handle.net/1721.1/106816 |
Similar Items
-
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
by: Guièze, R, et al.
Published: (2015) -
Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01) -
Celebrating 20 Years of IGHV Mutation Analysis in CLL
by: Nicholas Chiorazzi, et al.
Published: (2020-02-01) -
P664: GRADING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS FOR THE TREATMENT OF RELAPSED/REFRACTORY CLL.
by: S. Molica, et al.
Published: (2022-06-01) -
P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
by: Federico Pozzo, et al.
Published: (2023-08-01)